A New Lane Opens for Drug-Device Hybrids

EU's March 2026 pharma overhaul creates the first legal pathway for drug-device combination products

2 Jul 2026

Brussels has given drug-device combination products a legal home of their own. Final compromise texts published on 6 March 2026 replace two foundational pieces of EU pharmaceutical law, Directive 2001/83/EC and Regulation (EC) 726/2004, and introduce, for the first time, dedicated statutory routes for combining medicines with devices. Law firms Osborne Clarke and Ropes & Gray both confirmed the publication.

Manufacturers previously had to work around the rules rather than through them. No dedicated framework existed for combination products, so developers pieced together evidence using overlapping directives, often receiving conflicting guidance from one member state to the next. Under the new regime, applicants must instead demonstrate that the combined product, not each component separately, works safely and effectively as a whole.

That shift changes how companies build their evidence from the start. Pharmaceutical, engineering and clinical teams now need to coordinate early, rather than assembling data in silos and stitching it together before filing. Businesses that adjust their development plans ahead of implementation should move through review more quickly once regulators begin applying the rules. Those that wait may find themselves reworking submissions already underway, at considerable cost.

The reform extends further than devices alone. New pathways also cover medicines paired with non-device components, a change that touches drug categories gaining ground in oncology, rare disease treatment and digital therapeutics. Parexel analysts have pointed to the strategic choices now facing developers as the combination-product pipeline grows more complex.

Regulators have yet to finalize transition timelines, leaving one practical question still open for industry. Even so, companies are already revising product roadmaps, calculating that early adjustment costs less than a scramble later. For an industry accustomed to regulatory ambiguity around combination products, that alone marks a departure.

Whether the new framework delivers the faster, more predictable reviews its architects intend will depend on how consistently national authorities apply it once the transition period ends. March 2026 gives the sector a fixed point to plan against; implementation will show whether that clarity holds.